单唾液酸四己糖神经节苷脂应用于手足口病并发脑炎的疗效观察

目的: 观察单唾液酸四己糖神经节苷脂(GM-1)治疗手足口病合并脑炎的疗效及安全性。方法: 将本院2010年4月至11月收治的139例手足口病合并脑炎患儿,随机分为治疗组81例、对照组58例。两组均给予静脉用丙种球蛋白、甲基强的松龙及甘露醇、呋塞米降颅内压、抗病毒治疗等。在此基础上治疗组加用GM-1 20 mg加入5%GS 50 mL 静脉滴注,10~14 d 为一疗程。结果: 治疗组肌张力、惊跳、嗜睡、呕吐恢复正常时间分别为(8.0±3.2)、(4.2±1.0)、(3.6±1.3)、(2.8±0.8) d,对照组分别为(10.3±3.8)、(4.8±1.3)、(4.2±1.3)、(3.2±1.0)d,差异均有统计学意义(P＜0.05)。两组临床疗效比较,治疗组显效43例,有效29例,无效9例,总有效率 88.89%;对照组显效21例,有效22例,无效15例,总有效率 74.14%,治疗组疗效优于对照组(P＜0.05)。结论: GM-1治疗儿童手足口病合并脑炎可较快减轻临床症状,提高治愈率,且未见明显不良反应,安全有效。

Observation of therapeutic effect of GM-1 for HFMD combine with encephalitis

AIM: To observe the therapeutic effect of HFMD combine with encephalitis by monosialoteterahexosyl ganglioside (GM-1). METHODS: 139 cases in our hospital from April 2010 to November 2010 were randomly divided into two groups,one with 81 cases as a treatment group and another with 58 cases as control group. All of the two groups were accepted the treatment of GG＋MePr＋MNT+ FSM i.v. within antiviral therapy. The treatment group was added ivgtt of the 5%GS 50 mL with GM-1 20 mg, 10-14 days as one course of treatment. RESULTS: The times of Symptoms improved after treatment, including muscle tension, startle, lethargy, vomiting of treatment group were (8.0±3.2),(4.2±1.0),(3.6±1.3),(2.8±0.8) d, control group were (10.3±3.8),(4.8±1.3),(4.2±1.3),(3.2±1.0) d, each indicator had statistically significant difference (P<0.05). In treatment group,excellence 43 cases, utility 29 cases, ineffective 9 cases,the total effective rate was 88.89%.In control group, excellence 21 cases, utility 22 cases, ineffective 15 cases,the total efficiency rate was 74.14%.The trerapeutic effect of treatment group was better than that of control group (P<0.05). CONCLUSION: GM-1 can rapidly relieve the clinical symptoms, improve the recovery rate, and has no significant adverse reactions, is safe and effective.